A recently published study found that a blend of Citrus bergamia and Cynara cardunculus extracts supported vascular inflammation and oxidative stress in subjects with type 2 diabetes and non-alcoholic fatty liver disease.
A recently published study1 found that a synergistic extract of Citrus bergamia and Cynara cardunculus (Bergacyn, marketed by DolCas Biotech; Landing, NJ) supported vascular inflammation and oxidative stress in subjects with type 2 diabetes and non-alcoholic fatty liver disease. In the randomized, double-blind, placebo-controlled study, 80 subjects were divided into four groups, and given either placebo, 600 mg of Bergacyn, 600 mg of a standalone bergamot extract, or 600 mg of a standalone cynara extract blend.
Results showed that Bergacyn significantly reduced the measures of liver damage enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) by 18 and 15 points, respectively, compared to a 10-point average reduction in the stand-alone groups, and no change in the placebo group. Bergacyn also improved markers of oxidative stress, reduced inflammatory markers, and improved endothelial function compared to the placebo group.
“Bergacyn’s unique blending of a high-polyphenol extract of bergamot and a high-sesquiterpene extract of artichoke leaf showed a novel synergistic benefit that was more than additive, when compared to stand-alone, single doses of bergamot or cynara extract,” explains Dr. Shavon Jackson-Michel, director of medical and scientific affairs for DolCas. “The potentizing action as a function of the patented process used enhances Bergacyn’s bioactivity.”
1. Musolino V et al. “The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease.” Journal of Traditional and Complementary Medicine, Published online ahead of print on February 8, 2020